Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens

Andrea J. Feller; Robin McKenzie; David N. Taylor; Colleen C. Woods; Shannon L. Grahek; Dilara Islam; Malabi M. Venkatesan; Thomas L. Hale; August L. Bourgeois

doi:10.1016/j.vaccine.2011.09.030

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens

Andrea J. Feller, Robin McKenzie, David N. Taylor, Colleen C. Woods, Shannon L. Grahek, Dilara Islam, Malabi M. Venkatesan, Thomas L. Hale, August L. Bourgeois

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Accurately assessing mucosal immune responses to candidate vaccines remains a technical challenge. ELISPOT is widely used as a surrogate of mucosal immune response by directly enumerating circulating antibody secreting cells (ASCs), while antibody in lymphocyte supernatant (ALS) titers the total amount of antibody secreted by ASC ex vivo using ELISA. ALS is more practical than ELISPOT because the ASC supernatant is frozen for ELISA that can be conducted at any time, with any antigen, and in any laboratory. We compared IgA and IgG responses to serotype-specific Shigella LPS using ELISPOT and ALS in subjects following vaccination or infection with Shigella. ALS results correlated well with ELISPOT results, and the ALS method was both sensitive and specific for the detection of antibody responses against Shigella LPS. Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen.

Original language	English (US)
Pages (from-to)	8487-8489
Number of pages	3
Journal	Vaccine
Volume	29
Issue number	47
DOIs	https://doi.org/10.1016/j.vaccine.2011.09.030
State	Published - Nov 3 2011
Externally published	Yes

Keywords

ALS
ELISPOT
Mucosal immune response
Shigella

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2011.09.030

Cite this

Feller, A. J., McKenzie, R., Taylor, D. N., Woods, C. C., Grahek, S. L., Islam, D., Venkatesan, M. M., Hale, T. L., & Bourgeois, A. L. (2011). Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens. Vaccine, 29(47), 8487-8489. https://doi.org/10.1016/j.vaccine.2011.09.030

Feller, AJ, McKenzie, R, Taylor, DN, Woods, CC, Grahek, SL, Islam, D, Venkatesan, MM, Hale, TL & Bourgeois, AL 2011, 'Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens', Vaccine, vol. 29, no. 47, pp. 8487-8489. https://doi.org/10.1016/j.vaccine.2011.09.030

@article{b81519e048b04a7993bd800f4c75f4fe,

title = "Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens",

abstract = "Accurately assessing mucosal immune responses to candidate vaccines remains a technical challenge. ELISPOT is widely used as a surrogate of mucosal immune response by directly enumerating circulating antibody secreting cells (ASCs), while antibody in lymphocyte supernatant (ALS) titers the total amount of antibody secreted by ASC ex vivo using ELISA. ALS is more practical than ELISPOT because the ASC supernatant is frozen for ELISA that can be conducted at any time, with any antigen, and in any laboratory. We compared IgA and IgG responses to serotype-specific Shigella LPS using ELISPOT and ALS in subjects following vaccination or infection with Shigella. ALS results correlated well with ELISPOT results, and the ALS method was both sensitive and specific for the detection of antibody responses against Shigella LPS. Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen.",

keywords = "ALS, ELISPOT, Mucosal immune response, Shigella",

author = "Feller, {Andrea J.} and Robin McKenzie and Taylor, {David N.} and Woods, {Colleen C.} and Grahek, {Shannon L.} and Dilara Islam and Venkatesan, {Malabi M.} and Hale, {Thomas L.} and Bourgeois, {August L.}",

note = "Funding Information: This work was supported by the USAMRMC grant # DAMD17-01-D-0011 , by Johns Hopkins University School of Medicine GCRC grant # M01-RR00052 from the National Center for Research Resources, NIH , and by Salix Pharmaceuticals . A. Feller is supported by the DHHS , NIH , National Eye Institute Training Grant Number EY07127 , Clinical Trials Training Program in Vision Research . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of the WRAIR/NMRC, the Department of the Army or the Department of Defense. The authors would like to thank the staff of the Johns Hopkins University Center for Immunization Research and the WRAIR, as well as Dr. David Sack, for their help in preparing this manuscript.",

year = "2011",

month = nov,

day = "3",

doi = "10.1016/j.vaccine.2011.09.030",

language = "English (US)",

volume = "29",

pages = "8487--8489",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "47",

}

TY - JOUR

T1 - Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens

AU - Feller, Andrea J.

AU - McKenzie, Robin

AU - Taylor, David N.

AU - Woods, Colleen C.

AU - Grahek, Shannon L.

AU - Islam, Dilara

AU - Venkatesan, Malabi M.

AU - Hale, Thomas L.

AU - Bourgeois, August L.

N1 - Funding Information: This work was supported by the USAMRMC grant # DAMD17-01-D-0011 , by Johns Hopkins University School of Medicine GCRC grant # M01-RR00052 from the National Center for Research Resources, NIH , and by Salix Pharmaceuticals . A. Feller is supported by the DHHS , NIH , National Eye Institute Training Grant Number EY07127 , Clinical Trials Training Program in Vision Research . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of the WRAIR/NMRC, the Department of the Army or the Department of Defense. The authors would like to thank the staff of the Johns Hopkins University Center for Immunization Research and the WRAIR, as well as Dr. David Sack, for their help in preparing this manuscript.

PY - 2011/11/3

Y1 - 2011/11/3

N2 - Accurately assessing mucosal immune responses to candidate vaccines remains a technical challenge. ELISPOT is widely used as a surrogate of mucosal immune response by directly enumerating circulating antibody secreting cells (ASCs), while antibody in lymphocyte supernatant (ALS) titers the total amount of antibody secreted by ASC ex vivo using ELISA. ALS is more practical than ELISPOT because the ASC supernatant is frozen for ELISA that can be conducted at any time, with any antigen, and in any laboratory. We compared IgA and IgG responses to serotype-specific Shigella LPS using ELISPOT and ALS in subjects following vaccination or infection with Shigella. ALS results correlated well with ELISPOT results, and the ALS method was both sensitive and specific for the detection of antibody responses against Shigella LPS. Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen.

AB - Accurately assessing mucosal immune responses to candidate vaccines remains a technical challenge. ELISPOT is widely used as a surrogate of mucosal immune response by directly enumerating circulating antibody secreting cells (ASCs), while antibody in lymphocyte supernatant (ALS) titers the total amount of antibody secreted by ASC ex vivo using ELISA. ALS is more practical than ELISPOT because the ASC supernatant is frozen for ELISA that can be conducted at any time, with any antigen, and in any laboratory. We compared IgA and IgG responses to serotype-specific Shigella LPS using ELISPOT and ALS in subjects following vaccination or infection with Shigella. ALS results correlated well with ELISPOT results, and the ALS method was both sensitive and specific for the detection of antibody responses against Shigella LPS. Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen.

KW - ALS

KW - ELISPOT

KW - Mucosal immune response

KW - Shigella

UR - http://www.scopus.com/inward/record.url?scp=82455172069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455172069&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.09.030

DO - 10.1016/j.vaccine.2011.09.030

M3 - Article

C2 - 21939714

AN - SCOPUS:82455172069

SN - 0264-410X

VL - 29

SP - 8487

EP - 8489

JO - Vaccine

JF - Vaccine

IS - 47

ER -

Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this